BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2020;97:1287-96. [PMID: 32299680 DOI: 10.1016/j.kint.2020.01.035] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Thurman JM, Laskowski J, Nemenoff RA. Complement and Cancer-A Dysfunctional Relationship? Antibodies (Basel) 2020;9:E61. [PMID: 33167384 DOI: 10.3390/antib9040061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Shi W, Lv J, Lin L. Coagulopathy in COVID-19: Focus on vascular thrombotic events. J Mol Cell Cardiol 2020;146:32-40. [PMID: 32681845 DOI: 10.1016/j.yjmcc.2020.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
3 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
4 Ehren R, Habbig S. Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab. Pediatr Nephrol 2021;36:3281-2. [PMID: 34274988 DOI: 10.1007/s00467-021-05203-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
6 Williams K, Aggio D, Chen P, Anokhina K, Lloyd AJ, Wang Y. Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. Pharmacoeconomics 2021;39:901-12. [PMID: 34195967 DOI: 10.1007/s40273-021-01059-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2022:S2666-6367(22)00003-3. [PMID: 35017119 DOI: 10.1016/j.jtct.2022.01.003] [Reference Citation Analysis]
8 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175-87. [DOI: 10.1016/j.molimm.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
10 Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther 2022. [PMID: 35304755 DOI: 10.1111/jcpt.13642] [Reference Citation Analysis]
11 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
12 Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol 2021;36:889-98. [PMID: 33048203 DOI: 10.1007/s00467-020-04774-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
13 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]
14 Balduini C, Freson K, Greinacher A, Gresele P, Kühne T, Scully M, Bakchoul T, Coppo P, Dovc Drnovsek T, Godeau B, Gruel Y, Rao AK, Kremer Hovinga JA, Makris M, Matzdorff A, Mumford A, Pecci A, Raslova H, Rivera J, Roberts I, Scharf RE, Semple JW, Van Geet C. The EHA Research Roadmap: Platelet Disorders. Hemasphere 2021;5:e601. [PMID: 34476343 DOI: 10.1097/HS9.0000000000000601] [Reference Citation Analysis]
15 Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells 2021;10:148. [PMID: 33451011 DOI: 10.3390/cells10010148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Schmidt T, Gödel M, Mahmud M, Fischer L, Huber TB, Kluger MA, Grahammer F. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome. Transplantation Direct 2022;8:e1289. [DOI: 10.1097/txd.0000000000001289] [Reference Citation Analysis]
17 Menne J. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? Kidney Int 2020;97:1106-8. [PMID: 32444092 DOI: 10.1016/j.kint.2020.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
19 Kant S, Kronbichler A, Sharma P, Geetha D. Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. Am J Kidney Dis 2021:S0272-6386(21)00835-0. [PMID: 34508831 DOI: 10.1053/j.ajkd.2021.07.019] [Reference Citation Analysis]
20 Zipfel PF, Wiech T, Gröne HJ, Skerka C. Complement catalyzing glomerular diseases. Cell Tissue Res 2021;385:355-70. [PMID: 34613485 DOI: 10.1007/s00441-021-03485-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2021;100:225-37. [PMID: 33307104 DOI: 10.1016/j.kint.2020.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Duong SL, Prüss H. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics 2022. [PMID: 35043373 DOI: 10.1007/s13311-022-01184-0] [Reference Citation Analysis]
23 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 2021;12:696385. [PMID: 34795626 DOI: 10.3389/fneur.2021.696385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chung C. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother 2021;55:330-43. [PMID: 32715723 DOI: 10.1177/1060028020941852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review. Cureus 2021;13:e19476. [PMID: 34912617 DOI: 10.7759/cureus.19476] [Reference Citation Analysis]
27 Wang Y, Johnston K, Popoff E, Myren KJ, Cheung A, Faria C, Tomazos I. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ 2020;23:1503-15. [PMID: 33001704 DOI: 10.1080/13696998.2020.1831519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Chen Y, Shao S, Huang J, Gu Y, Cheng Y, Zhu X. Therapeutic Efficacy of a Trichinella Spiralis Paramyosin-Derived Peptide Modified With a Membrane-Targeting Signal in Mice With Antigen-Induced Arthritis. Front Microbiol 2020;11:608380. [PMID: 33424810 DOI: 10.3389/fmicb.2020.608380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep 2021;6:1603-13. [PMID: 34169200 DOI: 10.1016/j.ekir.2021.03.884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
31 Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res 2021;138:104226. [PMID: 34252400 DOI: 10.1016/j.mvr.2021.104226] [Reference Citation Analysis]
32 Giorgio C, Zippoli M, Cocchiaro P, Castelli V, Varrassi G, Aramini A, Allegretti M, Brandolini L, Cesta MC. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives. Biomedicines 2021;9:399. [PMID: 33917266 DOI: 10.3390/biomedicines9040399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Legendre C, Rebecca-Sberro-Soussan, Zuber J. Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney Int Rep 2021;6:1489-91. [PMID: 34169186 DOI: 10.1016/j.ekir.2021.04.036] [Reference Citation Analysis]
34 Romano R, Giardino G, Cirillo E, Prencipe R, Pignata C. Complement system network in cell physiology and in human diseases. Int Rev Immunol 2021;40:159-70. [PMID: 33063546 DOI: 10.1080/08830185.2020.1833877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Portilla D, Xavier S. Role of intracellular complement activation in kidney fibrosis. Br J Pharmacol 2021;178:2880-91. [PMID: 33555070 DOI: 10.1111/bph.15408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]